Transgender hormone therapy (male-to-female) orchiectomy still experience morning erections. Voluntary erections may or may not be possible, depending on the amount of hormones and/or antiandrogens being taken. Managing long-term hormonal regimens have not been studied and are difficult to estimate because research on the long-term use of hormonal therapy has not been noted. However, it is possible to speculate the outcomes of these therapies on transgender people based on the knowledge of the current effects of gonadal hormones on sexual functioning in cisgender men and women. Firstly, if one is to decrease testosterone in male-to-female gender transition, it is likely that sexual desire and
Male reproductive system during puberty causes the male secondary sexual characteristics to be manifested. the manifestation of secondary sexual characteristics include the growth of: Secondary development includes the increased activity of the eccrine sweat glands and sebaceous glands along with the darkening of the skin in the scrotal region. Chromosomal abnormalities can occur during fertilization impacting the development of the male reproductive system. The genotype of the male consists of a Y chromosome paired with an X chromosome. Female gender is determined by the absence of a Y chromosome. Some individuals are male who have the XX male syndrome and androgen insensitivity syndrome.